Real-time enrollment status for this platinum-resistant ovarian cancer clinical trial
Current Status
Recruiting
Checked: August 27, 2026 at 11:11 PM UTC
| NCT Number | NCT07226427 |
| Recruiting Status | Recruiting |
| Condition | Platinum-resistant Ovarian Cancer |
| Phase | PHASE1 |
| Target Enrollment | 100 participants |
| Active Locations | 7 sites in the US |
| Sponsor | Stemline Therapeutics, Inc. |
| Last Updated on CT.gov | July 6, 2026 (Jul 6, 2026) |
As of August 27, 2026: Clinical trial NCT07226427 is currently recruiting participants. This phase1 study for platinum-resistant ovarian cancer is actively seeking new participants at 7 locations across the United States. The study is sponsored by Stemline Therapeutics, Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07226427 is actively recruiting participants as of August 27, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 7 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07226427 was last updated Jul 6, 2026 (July 6, 2026). HelloStudys verifies this status automatically.